PEACE-2 Trial of Cabazitaxel with ADT and Radiotherapy in Very High-Risk Localized Prostate Cancer - Karim Fizazi
Karim Fizazi
Karim Fizazi presents PEACE-2, a phase 3 2×2 trial enrolling 761 patients with very high-risk localized prostate cancer randomized to ADT plus radiation with or without four cycles of cabazitaxel at 20 to 25 mg/m².
Large-Scale Data Linkage Reveals Genomic Differences in De Novo Metastatic Prostate Cancer - Shalini Moningi
Shalini Moningi speaks with Angela Jia about a real-world analysis evaluating the Decipher® Prostate Genomic Classifier in patients with de novo metastatic prostate cancer.
